Evolus(US:EOLS)2025-03-05 04:20Business Overview - Evolus aims to make the beauty experience delightful and achievable[9] - The company is building a brand focused on the younger demographic[11] - Evolus operates a unique cash-pay business model powered by strong digital capabilities[11, 34] Market Position and Growth - Jeuveau's share of the toxin market has grown to 13% in 2024[13] - The total addressable market expands by 78% with the addition of injectable HA gel portfolio[11] - The neurotoxin and filler markets are projected to grow to approximately $10 billion by 2028[15, 16] - Evolus International is expected to achieve $100 million in 2028[18] Financial Performance - The company anticipates total net revenues for 2025 to be between $345 million and $355 million[23, 114] - Evolysse and Estyme injectable HA gels are expected to contribute 8-10% of the total net revenue in 2025[103, 114] - Evolus projects at least $700 million in total net revenue and a non-GAAP operating income margin of at least 20% by 2028[115, 117]